Genscript

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript’s premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of June 30, 2024, GenScript's products and services have been cited by 103,600 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.